London · Pre-Seed–Series B · 14 people tracked
Also known as 4BIO PARTNERS LLP
Find your way into 4BIO Capital
3,502 people in our graph share verified history with the 4BIO Capital team — schools, employers, funds. One of them is your warm intro.
Investment thesis
4BIO Capital is a specialist life sciences venture capital firm concentrating on advanced therapies. The firm targets companies developing treatments that address significant unmet medical and social needs, positioning its investments to deliver both scientific innovation and social impact.
Source: firm website, verified Sep 15, 2026.
Team · 14 people
from the firm's website
Founder mafia
2 people who came through 4BIO Capital went on to found or lead other companies.
What they invest in
from 11 of 12 portfolio companiesBiotech ×10Deep Tech ×6Healthtech ×5Medical Devices ×5AI & Machine Learning ×2Consumer ×1Impact & Social Good ×1Longevity ×1
HQs:United States×5United Kingdom×1Japan×1
Investments · 12 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 22024 · 32023 · 12022 · 22020 · 111 dated
Hornet Therapeutics is a biotech company developing treatments for Epstein-Barr Virus (EBV) driven diseases, with a lead IDO-1 inhibitor (HTX-201) aimed at preventing EBV-implicated conditions such as post-transplantation lymphoproliferative disease.
BiotechMedical Devices
Christoph Hess(Co-founder (Professor))
March Bioscience is a cell therapy company assembling leading scientists and drug developers to advance cell therapy treatments.
BiotechMedical DevicesHouston, US
Sarah Hein(CEO, Co-Founder)inMaksim Mamonkin(Co-Founder, Chair Scientific Advisory Board)Malcolm Brenner(Co-founder)
BoardThomas Luby(Director)inPeter Olagunju(Director)inJoseph Petrosino(Director)
Co-investorsMission BiocapitalCancer FundFitz Gate VenturesModi VenturesPortal InnovationsTMC Venture Fund+1 more
Actithera develops a chemistry platform for targeted cancer treatment that optimizes radiation dose absorption in tumors while reducing exposure to healthy tissue, with flexibility to pair different radionuclides based on tumor characteristics.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Darshan Dalal(Chief Medical Officer)in
Co-investorsHadean VenturesM VenturesSofinnova PartnersBioqube Ventures
Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver.
BiotechDeep TechHealthtechHatfield, US
Lauren Kaskiel(Executive Officer)inRobert C. Getts(Executive Officer)Brian McVeigh(Executive Officer, Director)in
BoardDmitry Kuzmin(Director)Victor Stone(Director)Edward Mathers(Director)
Co-investorsNew Enterprise Associates (NEA)Amgen VenturesHatteras Venture PartnersJDRF T1D FundNorthpond VenturesTakeda Ventures+1 more
Hornet is a social networking and chat app for gay men and the broader queer community, offering messaging, a content feed, short videos, and discovery features.
ConsumerImpact & Social GoodMedia & EntertainmentSocial
Christof Wittig(Founder)inDamien BrenierinMitchell Geere
Co-investors500 GlobalMoai CapitalVentech China
LUCA Science develops mitochondrial therapies that supply functional, storable mitochondria to damaged or dysfunctional cells and tissues to restore cellular energy production, targeting conditions such as ischemia-reperfusion injuries including cerebral and myocardial infarction.
BiotechDeep TechHealthtechLongevity
Co-investorsFast Track InitiativeRemiges Ventures, Inc.DCI Partners Co. Ltd.
Trogenix develops precision genetic medicines for cancer treatment using proprietary Synthetic Super-Enhancers technology delivered via AAV vectors, targeting solid tumors with personalized in situ vaccinations.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Co-investorsACADEMY INVESTORLongeVCAIN VenturesIQ Capital
.jpeg){kind=logo}
Trogenix develops precision gene therapies for cancer using its Odysseus platform and Synthetic Super-Enhancer (SSE) technology, engineered DNA elements activated only in diseased cell states to selectively target and kill tumour cells while activating the immune system.
BiotechDeep TechHealthtech
Co-investorsAIN VenturesCalculus Capital Ltd.IQ CapitalLongeVC
ViaNautis develops targeted polyNaut nanovesicle (tPNV) delivery technology to advance cell and gene therapies and genetic medicines.
BiotechDeep TechMedical DevicesCambridge, GB
Co-investorsCambridge Angels groupOxford Investment Opportunity Network (OION)Origin CapitalUCB Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Cytospire TherapeuticsRay TherapeuticsRedpin Therapeutics
Portfolio news
latest coverage across their companiesRay Therapeutics · finsmes.com · Apr 21, 2026
Redpin Therapeutics · fiercebiotech.com · Aug 18, 2025
Actithera · arcticstartup.com · Jul 10, 2025
Principals & officers · per Companies House
what is this? ⓘDirector · British · since 2024
Director · British · since 2024
Director · British · since 2024
Dmitry Kuzmin — 25–50% of shares, 25–50% of voting rights, right to appoint and remove directors
Andrey Kozlov — 25–50% of shares, 25–50% of voting rights, right to appoint and remove directors
Frequently asked questions
- How many investments has 4BIO Capital made?
- 4BIO Capital has 12 tracked investments, including 5 dated in the last 24 months.
- What stage does 4BIO Capital invest at?
- 4BIO Capital invests at the Pre-Seed, Seed, Series A, Series B stages.
- What sectors does 4BIO Capital focus on?
- 4BIO Capital focuses on Biotech, Healthtech, Medical Devices.
- Where is 4BIO Capital located?
- 4BIO Capital is headquartered in London, GB.
Images
Co-investors · 12
Takeda Ventures, Inc. is the corporate venture capital arm of Takeda, making venture-based investments in therapeutic and platform-based companies to build the pharmaceutical company's pipeline and create strategic growth opportunities.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Northpond Ventures is a venture capital firm based in Bethesda, Maryland that invests in life sciences, technology, and related sectors.
Abingworth is a life science venture capital firm that backs early-stage biopharma and biotech companies, helping entrepreneurs translate scientific discoveries into new therapeutics.
Remiges Ventures is a venture capital firm focused on life sciences and drug discovery, backing biotech and therapeutics companies. It launched the RDiscovery Fund to incubate early-stage drug discovery projects.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.
BGF provides minority growth capital and support to entrepreneurial small and medium-sized businesses across the UK and Ireland, from university spinouts to established brands.
Pureos Bioventures is a venture capital firm that invests in private, innovative drug development companies, with a focus on next-generation biological drugs and drug formats to treat severe diseases.
Astellas Venture Management (AVM) is the wholly-owned corporate venture arm of Astellas, providing equity investments to private, early-stage biotechnology companies developing therapeutic programs and platform technologies for drug discovery.
82VS is a venture studio embedded within Alloy Therapeutics, a discovery platform and service provider, collaborating with academics, entrepreneurs, pharma, and VCs across company creation, drug discovery, and development.
Firms observed investing alongside 4BIO Capital, from public investor directories. Shared companies are the overlap with 4BIO Capital's recorded portfolio.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Innovestor is a Finnish investment manager active in venture capital, real estate, and energy storage, and also provides corporate venturing services.